Agilent Technologies last week completed its acquisition of Stratagene for $10.94 a share, or $246 million, gaining access to the firm’s array-related software and reagent kits as well as growing its headcount by 450 and gaining Stratagene’s operations in Texas, California, Japan, and The Netherlands.
 
Separately, Agilent said that it expects third-quarter revenue to decline between 2 percent and 4.8 percent year over year, though it is a 1.5-percent improvement over earlier predictions.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.